Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer, a life sciences company, successfully closed its initial public offering (IPO) with 10,592,106 shares of Class A common stock priced at $19.00 per share, raising approximately $201.3 million. The IPO includes the full exercise of underwriters' options for an additional 1,381,579 shares. Seer's stock began trading on the Nasdaq under the ticker symbol SEER on December 4, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley.